We work every day to transform patients’ lives through science. See our community guidelines: one.bms.com/3WHdbIG
Joined April 2009
- Tweets 8,959
- Following 1,029
- Followers 151,292
- Likes 1,512
4,221 Photos and videos
Jun 10
As the world gets ready for the 2026 #FIFAWorldCup, our fight to see patients win never ends. See why #BMSWontLose at bmswontlose.com
4
684
Jun 8
In the 2026 #FIFAWorldCup, every moment counts for players—just like it does for our patients.
Hear CEO Chris Boerner on why #BMSWontLose as we work to deliver the next breakthrough for those waiting: bit.ly/4az2xLw
1
9
1,127
Jun 8
#MEDIA: Today, we’re launching Investigating Myeloma, a #MultipleMyeloma awareness campaign in partnership with Mariska Hargitay, which spotlights the importance of ongoing scientific innovation, including a research approach called CELMoD. Read more: bit.ly/3SsuFtB
7
16
1,375
Jun 2
#MEDIA: New data will be presented at #ASCO26 for an EGFRxHER3 bispecific antibody-drug conjugate in triple negative breast cancer and in metastatic esophageal squamous cell carcinoma. Read more: bit.ly/43ME29S
3
12
1,951
Jun 1
#MEDIA: The FDA has accepted for Priority Review an sNDA for our treatment for adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). If approved, this would be the first cardiac myosin inhibitor to treat adolescents with oHCM: bit.ly/4a07AVa
3
14
1,420
Jun 1
#MEDIA: The European Commission approved the first immunotherapy-based treatment combination for newly diagnosed classical #HodgkinLymphoma in certain adult and pediatric patients. bit.ly/3Q9dGff
4
13
2,280
May 29
#MEDIA: Announcing late-breaking results at #ASCO26 from a Phase 3 trial evaluating an investigational therapeutic class called CELMoD for adult patients with relapsed or refractory #MultipleMyeloma. Read more: bit.ly/4nRyows
5
17
1,917
May 21
#MEDIA Chicago, here we come. #ASCO26
50 abstracts. 10 cancer types. At @ASCO we're sharing the latest data from our oncology portfolio and pipeline. May 29 – June 2. bit.ly/4ut6b1J
2
2
13
2,317
May 8
#MEDIA: Today, we announced European Commission approval of our oral treatment for adults living with active psoriatic arthritis (PsA) who have had an inadequate response or have been intolerant to prior disease-modifying antirheumatic therapy. Read more: bit.ly/4tjEK8X
1
1
15
1,804
May 4
Today, we kick off #BMSWontLose, where the energy of the 2026 #FIFAWorldCup meets the urgency of our mission to transform bold science into wins for patients around the globe. Discover more at bmswontlose.com.
1
6
1,756
May 4
#MEDIA: Today we launched Won’t Lose, a new campaign debuting ahead of the FIFA World Cup 2026™—leveraging a global cultural moment to reflect the relentless mindset that pushes bold science forward for patients who cannot wait. bit.ly/4tZF79Z
6
1,037
Mar 31
#MEDIA: Today, we announced the expansion of Standing in the Gaap, marking 10 years of work to address gaps and barriers in multiple myeloma care—including plans to launch one of the largest multiple myeloma surveys in the U.S. bit.ly/4tizSRU
3
1
10
2,133
Mar 29
#MEDIA: We’re showcasing full Phase 3 SCOUT‑HCM results at #ACC26, highlighting a potential treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Learn more about the data: bit.ly/4theMDz
2
16
1,846
Mar 28
MEDIA: At this year’s #SIRS2026, we’re presenting abstracts from our neuroscience portfolio, including new #schizophrenia data. Learn more here: bit.ly/4uUgEDM
1
3
16
1,653
Mar 23
#MEDIA: At #ACC26 we’re presenting new clinical and real-world insights in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). These data build on our research and highlight outcomes across diverse patient populations: bit.ly/4bqZMwV
5
14
1,773
Mar 20
#MEDIA: The @US_FDA and the European Commission approved immunotherapy-based treatment combinations for classical #HodgkinLymphoma in certain adult and pediatric patients. bit.ly/4duE2S8
6
16
2,295
Mar 11
#MEDIA: Announcing positive topline results from a Phase 3 trial evaluating our investigational CELMoD agent for adult patients with relapsed or refractory #MultipleMyeloma. bit.ly/3PvQpTW
5
6
22
5,527
Mar 7
#MEDIA: The @US_FDA approved our treatment for active psoriatic arthritis (PsA), bringing a new option for adults living with the condition. Learn more: bit.ly/40P53YR
4
1
19
2,556
Mar 3
VP and Head of Global Market Access, Cell Therapy Phung Osborn is a true leader working to increase patient access to cell therapies. A long-time advocate focused on overcoming barriers to care, we’re thrilled to celebrate Phung as our BMS @PhRMA 2026 #WorkingforCures Champion.
Mar 3
I am proud to announce this week’s #WorkingforCures champion, Phung Osborn from @bmsnews. Phung is a leading voice in expanding patient access to transformative CAR-T therapies and works closely with treatment centers, payers and patient organizations to improve understanding of cell therapy access barriers. Thank you, Phung, and congratulations.
1
1
12
2,007
Feb 26
Our Chairman and CEO Chris Boerner rang the @NYSE #ClosingBell alongside colleagues, underscoring our shared commitment to discovering, developing and delivering medicines that address serious diseases and improve patients’ lives around the world. #OneBMS
5
14
3,942